Whitehawk Therapeutics, Inc. (WHWK)

Market Cap	233.30M +194.8%
Revenue (ttm)	n/a -72.5%
Net Income	-115.81M
EPS	-1.67
Shares Out	49.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	220,301
Open	4.770
Previous Close	4.780
Day's Range	4.645 - 4.910
52-Week Range	1.570 - 5.495
Beta	0.71
Analysts	Buy
Price Target	6.50 (+37.71%)
Earnings Date	May 7, 2026

About WHWK

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: WHWK
• Website: https://ir.whitehawktx.com

Financial Performance

In 2025, Whitehawk Therapeutics's revenue was $7.15 million, a decrease of -72.50% compared to the previous year's $25.98 million. Losses were -$20.60 million, -67.66% less than in 2024.

Analyst Summary

According to 6 analysts, the average rating for WHWK stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 37.71% from the latest price.

Price Target

$6.5

(37.71% upside)

Analyst Consensus: Buy